Circulating Cell-free Genome Atlas Study

Mapping the Landscape of Genomic Cancer Signals in the Blood

The Circulating Cell-free Genome Atlas (CCGA) Study is a prospective, observational, longitudinal, study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer. The study is enrolling at least 15,000 participants across 142 sites in the United States and Canada. Approximately 70 percent of participants have cancer at the time of enrollment (newly diagnosed, and have not yet received treatment) and 30 percent do not have a known cancer diagnosis. Planned follow-up for all participants is at least five years to collect clinical outcome data.

Current Status: Enrolling

Early Detection Can Increase Survival

The earlier that cancer can be found, the better the chance of successful treatment. GRAIL and its research partners are enrolling participants in CCGA to identify patterns that could be used to detect many types of cancer, and to discover, develop, and validate a blood test for the early detection of cancer.

Collaborators

  • Avera Research Institute
  • Benaroya Research Institute at Virginia Mason
  • Christ Hospital Health Network - The Lindner Cancer Center Research Division
  • Cleveland Clinic
  • Dana Farber Cancer Institute
  • Guardian Research Network
  • Hartford HealthCare Cancer Institute
  • Icahn School of Medicine at Mount Sinai
  • Lahey Hospital & Medical Center
  • Mayo Clinic (Arizona, Florida, and Minnesota)
  • Memorial Sloan Kettering
  • Oregon Health & Science University Knight Cancer Institute
  • Tennessee Oncology
  • UHN Princess Margaret Cancer Centre (Canada)
  • University of Miami Sylvester
  • US Oncology Network

Eligibility

Participants enrolled in the study have either a new diagnosis of cancer and have not yet received treatment, or are individuals without a current or prior cancer diagnosis. All participants are 20 years of age or older and have provided written informed consent.

Visit Trial Site Website